Highly Selective CDK7 Inhibitor Q901 in Advanced Solid Tumors
Phase 1/2
130
about 4 years
18+
7 sites in AZ, CA, FL +4
What this study is about
This trial is testing a new drug called Q901, which blocks the activity of CDK7. It's being tested in people with advanced solid tumors who have not responded to other treatments. The goal is to see if Q901 can help shrink or control the cancer and how safe it is.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take KEYTRUDA® (pembrolizumab)
- 2.Take Q901
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary: Change in the area under curve (AUC) of Q901, Change in the maximum plasma concentration (Cmax) of Q901, Change in the time of maximum plasma concentration (Tmax) of Q901